153 222

Cited 10 times in

Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients.

 Jung Won Park  ;  Jin Ha Lee  ;  Ye Hyun Park  ;  Soo Jung Park  ;  Jae Hee Cheon  ;  Won Ho Kim  ;  Tae Il Kim 
 WORLD JOURNAL OF GASTROENTEROLOGY, Vol.23(28) : 5196-5205, 2017 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use* ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/mortality* ; Colorectal Neoplasms/pathology ; Diabetes Mellitus, Type 2/drug therapy* ; Diabetes Mellitus, Type 2/mortality ; Female ; Follow-Up Studies ; Humans ; Hypoglycemic Agents/therapeutic use* ; Kaplan-Meier Estimate ; Male ; Metformin/therapeutic use* ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Retrospective Studies ; Sex Factors ; Survival Rate ; Treatment Outcome
Colorectal cancer ; Metformin ; Sex ; Survival
AIM: To assess factors associated with the higher effect of metformin on mortality in diabetic colorectal cancer (CRC) patients, since the factors related to the effectiveness of metformin have not been identified yet. METHODS: Between January 2000 and December 2010, 413 patients diagnosed with both stage 3/4 CRC and diabetes mellitus were identified. Patients' demographics and clinical characteristics were analyzed. The effect of metformin on CRC-specific mortality and the interactions between metformin and each adjusted factor were evaluated. RESULTS: Total follow-up duration was median 50 mo (range: 1-218 mo). There were 85 deaths (45.9%) and 72 CRC-specific deaths (38.9%) among 185 patients who used metformin, compared to 130 total deaths (57.0%) and 107 CRC-specific deaths (46.9%) among 228 patients who did not use metformin. In multivariate analysis, survival benefit associated with metformin administration was identified (HR = 0.985, 95%CI: 0.974-0.997, P = 0.012). Interaction test between metformin and sex after adjustment for relevant factors revealed that female CRC patients taking metformin exhibited a significantly lower CRC-specific mortality rate than male CRC patients taking metformin (HR = 0.369, 95%CI: 0.155-0.881, P = 0.025). Furthermore, subgroup analysis revealed significant differences in CRC-specific mortality between the metformin and non-metformin groups in female patients (HR = 0.501, 95%CI: 0.286-0.879, P = 0.013) but not male patients (HR = 0.848, 95%CI: 0.594-1.211, P = 0.365). There were no significant interactions between metformin and other adjusted factors on CRC-specific mortality. CONCLUSION: We showed a strong sex-dependent difference in the effect of metformin on CRC-specific mortality in advanced stage CRC patients with diabetes.
Files in This Item:
T201704375.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Won Ho(김원호) ORCID logo https://orcid.org/0000-0002-5682-9972
Kim, Tae Il(김태일) ORCID logo https://orcid.org/0000-0003-4807-890X
Park, Soo Jung(박수정)
Park, Yehyun(박예현) ORCID logo https://orcid.org/0000-0001-8811-0631
Park, Jung Won(박정원)
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.